PHP
WHWK

Parkman Healthcare Partners’s Whitehawk Therapeutics WHWK Stock Holding History

Parkman Healthcare Partners’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-75,961
Closed -$550K – 105
2023
Q1 		$550K Buy
+75,961
New +$812K 0.12% 77
2021
Q3 		– Sell
-23,597
Closed -$598K – 83
2021
Q2 		$598K Sell
23,597
-43,149
-65% -$986K 0.13% 78
2021
Q1 		$1.29M Buy
66,746
+49,121
+279% +$1.13M 0.3% 69
2020
Q4 		$259K Sell
17,625
-2,375
-12% -$50.8K 0.07% 83
2020
Q3 		$450K Buy
+20,000
New +$421K 0.12% 82

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Parkman Healthcare Partners's WHWK Position: Q2 2023 in Review

Parkman Healthcare Partners sold out of Whitehawk Therapeutics (WHWK) in Q2 2023, closing a stake of 75,961 shares — an estimated $550K sold.

Parkman Healthcare Partners first reported a position in WHWK in Q3 2020 and held it in 5 quarters. The position peaked at $1.29M in Q1 2021. 67 funds tracked by Wall St. Rank hold WHWK as of Q2 2023.

  • Parkman Healthcare Partners reported no remaining Whitehawk Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 75,961 Whitehawk Therapeutics shares in Q2 2023, an estimated $550K.
  • Parkman Healthcare Partners first reported a position in Whitehawk Therapeutics in Q3 2020 and held it in 5 quarters.
  • Parkman Healthcare Partners's Whitehawk Therapeutics position peaked at $1.29M in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2023.

Based on Parkman Healthcare Partners's 13F filing for Q2 2023, filed 11 Aug 2023.